Vosevi União Europeia - português - EMA (European Medicines Agency)

vosevi

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatite c, crônica - antivirais para uso sistêmico - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (consulte as secções 4. 2, 4. 4 e 5.

Biktarvy União Europeia - português - EMA (European Medicines Agency)

biktarvy

gilead sciences ireland uc - bictegravir, emtricitabina, tenofovir alafenamide, fumarato - infecções por hiv - antivirais para uso sistêmico - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ver secção 5.

HOMEOFLAN Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

homeoflan

farmÁcia e laboratÓrio homeopÁtico almeida prado ltda - rhus toxicodendron, atropa belladonna, aconitum napellus, symphytum officinale, hypericum perforatum, arnica montana - medicamentos dinamizados compostos

Rekambys União Europeia - português - EMA (European Medicines Agency)

rekambys

janssen-cilag international nv - rilpivirine - infecções por hiv - antivirais para uso sistêmico - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Rukobia União Europeia - português - EMA (European Medicines Agency)

rukobia

viiv healthcare b.v. - fostemsavir trometamol - infecções por hiv - antivirais para uso sistêmico - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.